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Abstract 
Introduction: Preterm delivery is associated with an increased risk of newborn morbidity and 
mortality. Respiratory distress syndrome (RDS) is the most common comorbidity. It has been 
proven that this syndrome can be prevented with the administration of prenatal corticosteroids 
to women at threat of preterm delivery before 35 weeks of gestational age. 
Aim: To evaluate the risk factors, severity, co-morbidities and mortality of this condition in 
newborns less than 35 weeks of gestational age and to assess the association between the 
elapsed time since the administration of the last dose of a full cycle of corticosteroids and the 
frequency and severity of RDS. 
Methods: In this descriptive retrospective study were included all newborns below 35 weeks of 
gestational age born at our center between January 1, 2012 and December 31, 2014 and 
admitted in Neonatal Intensive Care Unit (NICU). We excluded newborns with major 
malformations, chromosomopathies, hydrops or congenital TORCH infection. 
Results: A total of 234 newborns were studied. Eighty-three (35.5%) newborns had RDS and 
151 (64.5%) remained without RDS. Prenatal corticosteroids were used in 90.1% of all 
newborns. When adjusted to the severity of RDS, a higher birth weight and a higher gestational 
age were associated with a significant reduction in mortality. The use of vasopressor support 
was significantly associated with an increase of mortality.  
Conclusion: Clinical chorioamnionitis, placental abruption, abnormal umbilical flow, and 
caesarean section were more frequent in infants with RDS. The use of peripartum antibiotics 
was significantly less frequent in infants with RDS. The last dose of a full cycle of prenatal 
corticosteroids must be given at least 10.5 hours before the delivery to prevent RDS.  
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Introduction 
Preterm delivery is associated with an increased risk of newborn morbidity and death. 
Respiratory distress syndrome (RDS) is its most common consequence and cause of morbidity 
in these newborns. [1-3] 
The administration of prenatal corticosteroids to women at threat of preterm delivery before 35 
weeks of gestational age has been proved to prevent RDS by increasing maturation of fetal lung 
and other tissues. [4, 5]. Prenatal corticosteroids have also been associated to a diminished risk 
of intraventricular hemorrhage (IVH), necrotizing enterocolitis (NEC), early sepsis and neonatal 
death. [2, 4]  
The major benefit of prenatal corticosteroids is observable when delivery occurs between 24 
hours and seven days after the beginning of therapy, but the effect seems to be diminished 14 
days after the administration. [2-4, 6] 
The most recent evidences showed that multiple courses were not recommended due to 
associations with reduced fetal growth, increased risk of adrenal suppression and due to failure 
to reduce the risk of death. [2, 7, 8] However, according to the 2013 Update of the European 
Consensus Guidelines on the Management of Neonatal RDS in Preterm Infants, a rescue course 
can be administered if more than two to three weeks have passed since the first course, in 
women at threat of preterm delivery and gestational age below 33 weeks. [6] 
The natural progression of RDS consists of a state of pulmonary insufficiency, caused by a 
deficiency of surfactant production in fetal lungs with structural immaturity, starting at delivery 
and followed by an increase in severity throughout the first two days of life. [2, 6]. If not 
treated, the disease can progress to respiratory failure and sometimes to death of the newborn. 
[6] 
Risk factors for this pathology are multiple gestation, maternal diabetes, chorioamnionitis, 
caesarean section, male sex, fifth minute Apgar score lower than seven, low birth weight and 
low gestational age. [9, 10] Prenatal corticosteroid therapy and preterm rupture of membranes 
reduce the risk of RDS. [10] 
This study aims to evaluate the risk factors, severity, co-morbidities and mortality of RDS in 
newborns less than 35 weeks of gestational age and to assess if the elapsed time from 
administration of the last dose of a full cycle of corticosteroids influences the frequency and 
severity of RDS. 
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Methods 
The authors performed a descriptive retrospective study of all newborn infants less than 35 
weeks of gestational age born between January 1, 2012 and December 31, 2014 at Hospital São 
João, admitted to the Neonatal Intensive Care Unit (NICU). Those with major malformations, 
chromosomopathies, hydrops or congenital TORCH (Toxoplasmosis; Others such as syphilis, 
varicella-zoster or parvovirus B19; Rubella; Cytomegalovirus; and Herpes) infection were 
excluded. 
The demographic, prenatal, delivery, and placental data, as well as information regarding 
evolution in NICU, treatment at discharge and necropsy results of deceased newborns were 
collected from clinical charts and retrospectively analyzed. 
RDS was diagnosed by a combination of clinical and radiographic features according to the 
criteria of the 2013 Update on the European Consensus Guidelines on the Management of 
Neonatal Respiratory Distress Syndrome in Preterm Infants. [6] These criteria are: (1) PaO2 < 
50 mmHg or central cyanosis in room air or a need for supplemental oxygen to maintain PaO2 > 
50 mmHg or to maintain oxygen saturation > 85% within the first 24 hours of life and; (2) a 
chest radiography consistent with RDS (reticulogranular appearance to lung fields with or 
without low lung volumes and air bronchograms) within the first 24 hours of life. [6] For 
practical purposes, we classified RDS in grades I to III according to the radiographic results (I - 
light, slight reticulogranular appearance; II - moderate, reticulogranular appearance with air 
bronchograms; III – severe, unclear cardiac borders or white lung).  [11] 
Gestational age (completed weeks) was determined by menstrual age in women with regular 
menstrual cycles, by ultrasonography when a discrepancy of two or more weeks between 
menstrual age and ultrasonographic age occurred or in the absence of a menstrual date, or by the 
New Ballard Score in the absence of obstetrical indexes. [12] Intrauterine growth restriction was 
defined as a birth weight below the 3
rd
 centile of Fenton`s growth charts. [13] Histological 
chorioamnionitis classification was made according to the method proposed by Blanc WA 
(stage I: intervilositis, stage II: chorionitis, stage III: chorioamnionitis). [14] Funisitis was 
defined as polymorphonuclear leukocytes in the wall of umbilical vessels or in Wharton’s jelly. 
[15] Villitis was diagnosed by the presence of a mononuclear infiltrate in the villous tree. [16] 
Vasculitis was defined as a polymorphonuclear leukocytes infiltrate in the chorionic or 
umbilical vessel walls. [17]  
Bronchopulmonary dysplasia (BPD) was diagnosed when a requirement for supplementary 
oxygen persisted for at least 28 days after delivery associated to characteristic radiographic 
features. Classification was according to the National Institutes of Health consensus criteria. 
[18] Patent ductus arteriosus (PDA) was confirmed by echocardiography with Doppler. [19, 20] 
NEC was defined by clinical findings, such as feeding intolerance longer than 24 hours and 
abdominal distention, the presence of radiological features such as intramural air, perforation or 
meconium plug syndrome or by definitive surgical findings. NEC was classified according to 
modified Bell staging criteria. [21]  IVH was diagnosed when transfontanellar ultrasound 
showed intraventricular bleeding confined to the periventricular area (grade 1), without 
ventricular dilatation (grade 2), with ventricular dilatation (grade 3) or with parenchymal 
involvement (grade 4). [22] Periventricular leukomalacia (PVL) was diagnosed when a 
hypoechoic cyst in the periventricular white matter was observable in the ultrasound. [22] 
Retinopathy of prematurity (ROP) was diagnosed and graded by ophthalmologists according to 
the International Classification of Retinopathy of Prematurity revised. [23] Sepsis was 
suspected in the presence of positive laboratory findings in patients with suggestive clinical 
features and diagnosed when a blood culture turned out to be positive. [22] Pneumonia was 
diagnosed by a combination of clinical and laboratory findings, and a chest radiographic 
showing patchy infiltrate, granularity, air bronchogram or consolidation. [24] Pneumothorax 
was suspected by clinical findings and confirmed by a chest radiographic showing air in the 
pleural space.  [25] 
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According to the Protocol of Gynecology and Obstetrics Department of our hospital, the 
prenatal therapy with corticosteroids is performed in mothers with 34 or less weeks of 
gestational age at threat of preterm labor. Betamethasone (2 doses of 12mg separated by 24 
hours) was used until February of 2014. Dexamethasone (4 doses of 6mg every 12 hours) was 
used since March of 2014. A rescue cycle is given to mothers who maintain criteria for 
corticosteroids therapy after a medical team decision. 
Surfactant therapy, poractant alfa, was given to newborns according to the protocol of our unit, 
in an initial dose of 200 mg/kg and, if needed (RDS with a persistent need of FiO2 > 0,4), 
subsequent doses of 100 mg/kg.  
Postnatal intravenous corticosteroids were administrated according to DART protocol when 
indicated. [26] 
The statistical analysis was performed using SPSS® for Windows, version 20. Continuous 
variables were characterized by mean (± standard deviation) or median (medium-maximum) if 
they had symmetric or asymmetric distribution respectively and categorical variables by 
absolute and relative frequencies. To compare continuous variables parametric tests 
(independent t test and One-Way ANOVA) or non-parametric tests (Mann Whitney-U test and 
Kruskal Wallis test) were used if they had two or more than two categories, and Chi-Squared or 
Fisher’s exact test to compare categorical variables, the latter for expected values less than 5. A 
multivariate analysis by logistic regression was performed to evaluate predictive factors of 
severity and mortality.  Receiver operating characteristic (ROC) curve was performed to study 
the time between last dose of a full cycle of corticosteroids and delivery and the risk of RDS. A 
p value less than 0.05 was considered statistically significant. 
This study protocol has been approved by the ethics committee of our hospital. 
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Results 
Two hundred and thirty-four newborns were included in this study. Eighty-three (35.5%) 
newborns had RDS and 151 (64.5%) remained without RDS. Seventeen (7.3%) infants deceased 
during the stay in NICU.  
The demographic and prenatal data of newborns are shown in table 1. Both mean birth weight 
and median gestational age were significantly lower in the RDS group (p<0.0001). There were 
no differences in maternal diseases between the two groups. However, pregnancy 
complications, such as clinical chorioamnionitis, placental abruption and abnormal umbilical 
flow, were significantly higher in newborns with RDS (p=0.002, p=0.030 and p=0.007, 
respectively). Prenatal corticosteroids were administered in 90.2% of the newborns with RDS 
and in 90.1% of those without RDS. The first corticosteroid cycle was completed in 67.6% of 
the newborns with RDS and in 70.6% of those without RDS. Betametasone was the most used 
corticosteroid (76.2%). The median time between the last dose of a full cycle of corticosteroids 
and delivery in infants with RDS was lower than in infants without RDS (59.0 hours and 81.5 
hours, respectively). Peripartum antibiotics were prescribed in 47.7% mothers of newborns 
without RDS and in 32.5% mothers of newborns with RDS (p=0.025). Regarding the placental 
histology, there were no statistically significant differences between newborns who had RDS 
and those without RDS. 
The delivery and evolution in neonatal intensive care unit are represented in table 2. Caesarean 
section was the preferred method of delivery (68.7% in infants with RDS and 54.3% in those 
without). The difference of the percentage of caesarian section between infants with and without 
RDS was significant, being higher in newborns with RDS (p= 0.032). The vaginal delivery was 
significantly more frequent in newborns without RDS (p=0.032). An Apgar score at first and 
fifth minutes lower than seven was significantly more common in infants with RDS (both with 
p<0.0001). Resuscitation and early invasive ventilation were significantly more frequent in 
infants who had RDS (both with p<0.0001). Early nasal CPAP was slightly more used in 
newborns with RDS, but the difference was not significant. With the exception of 
periventricular leukomalacia and hydrocephalus, all of the neonatal morbidities were 
significantly more frequent in newborns with RDS. The most common neonatal morbidities in 
all infants were PDA and anemia with red blood cells transfusion need (25.2% and 24.8%, 
respectively). Hydrocephalus and seizures were the least frequent neonatal morbidities and only 
occurred in infants with RDS (0.4% and 1.3%, respectively). Vasopressor support was 
significantly more needed in newborns with RDS (p<0.0001) with a median of 2.5 days of 
vasopressor support in infants with RDS and 1.0 in infants without RDS. Infants who had RDS 
had a significant higher need for oxygen therapy and invasive ventilation (p<0.0001), with a 
median duration of 6.0 and 5.0 days, respectively. Parenteral nutrition was used significantly 
more frequently and for a higher median number of days in newborns with RDS (both with 
p<0.0001). Parenteral nutrition was administrated in 93.8% and for a median of 14.0 days in 
infants with RDS and in 66.7% and for a median of 7.0 days in infants without RDS. Newborns 
with RDS had a significantly higher need for surfactant, bronchodilators and inhaled 
corticosteroids (p<0.0001). None of the infants without RDS needed any of these therapies. 
Postnatal intravenous corticosteroids were administrated in seven infants with RDS (8.4%) and 
in none without RDS (p=0.001). The total median number of days of stay in NICU was 15.0 and 
it was significantly higher in infants with RDS, who stayed a median of 33.0 days (p<0.0001). 
Fifty nine (25.2%) infants were transferred to another NICU to continue treatment. The 
percentage of transferred patients was significantly higher in the group of infants without RDS 
(12.0% in infants with RDS and 32.5% without RDS; p=0.001). The newborns had a median of 
6.0 days in our unit until transference, being the median number of days higher in those with 
RDS (9.5 days). Bronchodilators, inhaled corticosteroids and oxygen therapy were prescribed as 
treatment at discharge only to the group with RDS. Inhaled corticosteroids were the most 
commonly used (14.5%). All of the 17 deceased newborns had RDS (20.5%) and the global 
mortality rate was 7.3% (p<0.0001). The most common causes of death were grade IV 
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intraventricular hemorrhage and multiorgan dysfunction. Each of these pathologies caused the 
death of six newborns with RDS. There was also one newborn deceased due to arrhythmia, one 
due to extreme prematurity, two due to pulmonary hypoplasia and one due to pulmonary 
hemorrhage. Eight of the deceased newborns were autopsied (47.1%). Pulmonary pathology 
findings were present in seven autopsies. Two newborns had BPD, two showed respiratory 
distress syndrome findings, two had bilateral pneumonia and one had massive pulmonary 
hemorrhage.  
Table 3 reports the differences in demographics and clinical characteristics according to severity 
of RDS. Thirty-five infants had mild RDS, 32 had moderate RDS and 16 had severe RDS. 
Gestational age was lower in more severe forms of RDS (p=0.014). Multiple gestation was 
significantly more frequent in infants with more severe grades of RDS (p=0.025). A full first 
cycle of corticosteroids was less frequent in infants with severe RDS (p=0.013). In more severe 
stages of RDS, the newborns needed early invasive ventilation more frequently (p=0.010). 
Patent ductus arteriosus with surgical treatment, periventricular leukomalacia and 
thrombocytopenia with platelet transfusion were more frequent in more severe stages of RDS. 
The need for vasopressor support, oxygen therapy and invasive ventilation were significantly 
higher (p=0.003, p=0.032 and p=0.016, respectively) in infants with higher grades of RDS. The 
surfactant was given according to the severity of RDS (p=0.001). 
Higher request for invasive ventilation and higher median number of surfactant doses were 
predictive factors of severity of RDS, when adjusted to birth weight and gestational age [OR= 
3.0, 95% CI (1.04-8.67) and OR= 3.2, 95% CI (1.46-6.97)]. 
Lower birth weight and lower gestational age, when adjusted to RDS severity, were predictive 
factors of mortality [OR= 0.990, 95% CI (0.98-0.99) and OR= 0.459, 95% CI (0.31-0.68)]. The 
need for vasopressor support, when adjusted to RDS severity, was also a predictive factor of 
mortality [OR= 14.4, 95% CI (3.2-63.6)]. 
The ROC curve identified a cut-off lower than 10.5 hours between the last dose of a full cycle 
of corticosteroids and the delivery as a higher risk of onset of RDS. The sensibility value of this 
cut-off was 80.0%. Another ROC curve also determined a cut-off lower than 6.5 elapsed hours 
between the last dose of a full cycle of corticosteroids and the delivery as a higher risk of onset 
of moderate to severe RDS. The sensibility value of this cut-off was 83.3%. 
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Discussion 
The prevalence of RDS in newborns with less than 35 weeks of gestational age was 35.5% in 
our samples, which is similar to previous studies. [2] Lower gestational age, lower birth weight, 
clinical chorioamnionitis, placental abruption, abnormal umbilical flow, caesarean section, and 
first and fifth minutes Apgar score lower than seven were more frequent in infants with RDS, 
which is consistent with the literature. [9, 10, 27, 28] 
Lower gestational age and multiple gestation were significantly more frequent in more severe 
grades of RDS, as it has been shown by others. [29]  
It has been shown that prenatal corticosteroids reduce the risk of RDS. [6] However, in our 
study, because corticosteroids were used in a high percentage of cases (90.1%), we could not 
find a significant difference in the administration of corticosteroids between infants with or 
without RDS and between the different grades of severity of RDS. However, a full cycle was 
associated with less severe forms of the condition. These results show the importance of using 
complete corticosteroid cycles in the prevention of more severe grades of RDS.  
Peripartum antibiotics were significantly less prescribed in infants with RDS, being consistent 
with what was found by Cousens, S. et al. [30] This could be because chorioamnionitis is 
reduced by peripartum antibiotics, leading to a higher gestational age and reducing the incidence 
of RDS. [31] 
The newborns with RDS had a significantly higher need for resuscitation and early invasive 
ventilation. The latter one was also more needed according to the severity of RDS, as expected, 
since this is the management of infants with RDS.  
BPD, a complication associated with the premature lung injury usually occurring after RDS and 
more frequent in more immature infants, also occurred in our study in newborns with RDS with 
an incidence of 18.1%. [32] 
In our study, PDA was the most common neonatal morbidity, affecting 25.2% of all newborns 
and 50.6% of those with RDS, data according to the literature. [33] Surgical treatment for PDA 
was only needed in six infants with RDS, because most of PDA closes spontaneously or with 
pharmacological treatment.  
Only newborns with RDS had pneumonia (7.2%). Invasive ventilation and chorioamnionitis in 
infants with RDS are two risk factors that increase the likelihood of pneumonia. [24] 
Pneumothorax only occurred in infants with RDS (9.6%), probably due to the higher incidence 
of clinical chorioamnionitis and resuscitation attempts, which are risk factors for this condition. 
[25] 
Intraventricular hemorrhage (≥ grade 3) and sepsis had a significantly higher incidence in 
infants with RDS. This could be due to the differences found in the administration of a full 
cycle of prenatal corticosteroids in the different grades of RDS because, according to the 
literature, corticosteroids reduce the incidence of IVH and sepsis. [2, 4] 
Periventricular leukomalacia was significantly more frequent in preterms with more severe 
grades of RDS. Infants with severe RDS had a higher need for oxygen therapy and invasive 
ventilation, known risk factors for periventricular leukomalacia, which could explain the 
association between leukomalacia and a higher severity of RDS. [6] 
RDS was associated with a significantly higher incidence of ROP (≥ grade 2) in our study. The 
major risk factors to ROP are prematurity, low birth weight and oxygen therapy, which are 
common in newborns with RDS. [6]  
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Other observed morbidities, such as atelectasis, seizures, acute renal failure, thrombocytopenia 
with platelet transfusion, anemia with red blood cells transfusion and gastroesophageal reflux, 
were significantly more frequent in infants with RDS, justifying the necessity for RDS 
prevention.  
Vasopressor support was more used in newborns with RDS, namely in more severe forms. It 
matched our expectations due to the higher morbidity that occurred in newborns with RDS and 
due to the higher severity of RDS in those newborns. 
As we expected, oxygen therapy was significantly more used in infants with RDS and with 
more severe grades of RDS. It was also used for a significantly higher median number of days. 
Invasive ventilation was only needed on infants with RDS and this difference of requirement for 
invasive ventilation was significant. Fifty-seven (68.7%) infants with RDS needed invasive 
ventilation for a median of 5.0 days. When comparing the different grades of RDS, invasive 
ventilation was more frequent in the more severe grades. These results were expected due to 
oxygen therapy and invasive ventilation being the management for RDS. According to the 
literature, invasive ventilation is necessary in a significant number of preterm infants with RDS 
who fail on CPAP, despite this being injurious to lungs. [6] 
Parenteral nutrition was significantly more used in infants with RDS and for a higher median 
number of days. These results were expected because infants with RDS had lower gestational 
age and birth weight, needing a longer parenteral nutrition. [6] 
Surfactant was required by 67 (80.7%) of the newborns with RDS, with a median of one dose. 
These results were expected because surfactant (prophylactic or as rescue therapy) is used as 
management of RDS and reduces the risk of pneumothorax and neonatal death in infants with 
RDS or at risk of developing it. [6] Surfactant was significantly more administrated in infants 
with more severe grades of RDS. The median surfactant dose was one in mild and moderate 
RDS and two in severe RDS. This matched our expectations, since the management of ongoing 
RDS includes a rescue therapy with two or more doses of surfactant. [6] 
Postnatal intravenous corticosteroids were used in seven (8.4%) newborns with RDS, because 
they facilitated the extubation procedure and reduced BPD. [6]  
Bronchodilators and inhaled steroids were both used in 11 (13.3%) of the newborns with RDS 
during the hospitalization in NICU. These therapies are used in a late period of the management 
of RDS or in an early period of BPD. [32] At discharge, eight (9.6%) newborns with RDS were 
medicated with bronchodilator, 12 (14.5%) with inhaled corticosteroids and 8 (9.6%) with 
oxygen. These results could be due to more severe forms of BPD in those infants.   
Infants with RDS had a significantly higher median number of days of hospitalization in NICU. 
Infants with RDS were hospitalized for a median of 33 days, with a number of hospitalization 
days between one and 191. Infants without RDS had a median of only 11 days of hospitalization 
in NICU, with a minimum of one day and a maximum of 61 days. Probably the infants with 
lower median number of days of hospitalization were transferred to another NICU to continue 
the treatment. Infants without RDS were significantly more transferred to another NICU to 
continue the treatment. The median number of days until transference was lower in infants 
without RDS. These results were expected due to the lower morbidity in those infants. 
As expected, the mortality rate was significantly higher in newborns with RDS. This could be 
because those infants have more risk factors for the death causes. Probably the deceased infants 
were those with the most severe grades of RDS, which also are those that had a significantly 
lower completion of the cycle of prenatal corticosteroids. Twelve deceased infants with RDS 
died due to grade IV intraventricular hemorrhage and multiorgan dysfunction, probably because 
they were not given corticosteroids before birth, or the given corticosteroids did not have an 
appropriated therapeutic effect due to several causes, including suboptimal administration 
timing or incomplete cycles. [6] Arrhythmia, extreme prematurity, pulmonary hypoplasia and 
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pulmonary hemorrhage are associated with immaturity, low birth weight and low gestational 
age, explaining the death of the other four infants with RDS. [34] 
As we expected, a higher request for invasive ventilation and a superior median number of 
surfactant doses, when adjusted to birth weight and gestational age, were associated with a 
significantly higher severity of RDS. This could be due to these therapies, used more frequently 
in newborns with more severe disease, being the management of RDS. [6] 
When adjusted to the severity of RDS, a higher birth weight and a higher gestational age were 
associated with a significant reduction in mortality. These results were compatible with the 
literature, according to which gestational age is the most important predictor of survival. The 
lower the gestational age and birth weight, the higher the risk of death. [35] The opposite 
occurred with the need for vasopressor support, which was significantly associated with an 
increased mortality. This result could be due to the higher morbidity that occurred in newborns 
with RDS. 
In our study, a time between the last dose of a full cycle of prenatal corticosteroids and the 
delivery lower than 10.5 hours was associated with a higher risk of onset of RDS, with a 
sensibility of 80%. An elapsed time between the last dose of a full cycle of prenatal 
corticosteroids and the delivery lower than 6.5 hours was associated with a higher risk of onset 
of moderate to severe RDS, with a sensibility of 83.3%. According to the literature, it was 
determined that the optimal interval between the start of corticosteroid treatment and the 
delivery is more than 24 hours and less than seven days, which is consistent with the time 
periods found in our study. [6] 
Our study had some limitations. Firstly, as a descriptive retrospective study, it probably has 
biases, including misclassification bias. Secondly, prenatal corticosteroid administration 
regimens changed since March 2014, which may have been a confounding factor in the type of 
prenatal management. However, it was not our aim to compare the effect of both drugs used in 
prevention of RDS, which have shown a similar effect. Prospective studies with adequate 
sample sizes could be useful to a better understanding of the morbimortality in these preterm 
newborns. 
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Conclusion 
Clinical chorioamnionitis, placental abruption and abnormal umbilical flow are risk factors for 
RDS. Peripartum antibiotherapy is indirectly related to prevention of RDS. 
Newborns with RDS have more frequently neonatal co-morbidities, namely BPD, PDA, IVH (≥ 
grade 3), ROP (≥ grade 2), sepsis, pneumonia, pneumothorax, acute renal failure, 
thrombocytopenia with platelet transfusion, anemia with red blood cells transfusion and 
gastroesophageal reflux. 
A full cycle of prenatal corticosteroids was fundamental to prevent higher grades of severity of 
RDS. 
Higher gestational age and birth weight were associated with a significant reduction in 
mortality. Vasopressor support, on the other hand, was associated with an increased mortality. 
Delivery in less than 10.5 hours since the last dose of a full cycle of prenatal corticosteroids was 
associated with a higher risk of onset of RDS, with a sensibility of 80%. A higher risk of onset 
of moderate to severe RDS occurred in newborns born in less than 6.5 hours since the last dose 
of a full cycle of prenatal corticosteroids, with 83.3% of sensibility. 
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Tables and Figures 
Table 1 – Demographic and prenatal data 
 Total 
(n=234) 
RDS 
(n=83) 
Without RDS 
(n=151) 
p 
Gender, n (%)     
 Male 134 (57.3) 44 (53.0) 90 (59.6) 0.330
*
 
 Female 100 (42.7) 39 (47.0) 61 (40.4) 0.330
*
 
Birth weight (grams), mean (±SD) 1658 (±578) 1225 (±516) 1896 (±462) <0.0001
§
 
Gestational age (weeks), median (min-max) 32 (23-34) 30 (23-34) 33 (27-34) <0.0001
¥
 
Intrauterine growth restriction, n (%) 39 (16.7) 18 (21.7) 21 (13.9) 0.127
*
 
Multiple gestation, n (%) 81 (34.6) 24 (28.9) 57 (37.7) 0.174
*
 
Maternal diseases, n (%)     
 Chronic hypertension 23 (9.8) 12 (14.5) 11 (7.3) 0.078
*
 
 Human Immunodeficiency Virus infection 1 (0.4) 0 1 (0.7) 0.999
∞
 
 Hepatitis B infection 2 (0.9) 1 (1.2) 1 (0.7) 0.999
∞
 
Pregnancy complications, (%)     
 Gestational diabetes 21 (9.0) 10 (12.0) 11 (7.3) 0.223
*
 
 Gestational hypertension 13 (5.6) 3 (3.6) 10 (6.6) 0.390
∞
 
 Pre-eclampsia 46 (19.7) 17 (20.5) 29 (19.2) 0.814
*
 
 HELLP syndrome
**
 7 (3.0) 4 (4.8) 3 (2.0) 0.249
∞
 
 Clinical chorioamnionitis 13 (5.6) 10 (12.0) 3 (2.0) 0.002
∞
 
 Placental abruption 21 (9.0) 12 (14.5) 9 (6.0) 0.030
*
 
 Abnormal umbilical flow 34 (14.5) 29 (22.9) 15 (9.9) 0.007
*
 
 Hydramnios 7(3.0) 3 (3.6) 4 (2.6) 0.701
∞
 
 Oligoamnios 9 (3.8) 5 (6.0) 4 (2.6) 0.286
∞
 
Prenatal Steroids, n (%) 210 (90.1) 74 (90.2) 136 (90.1) 0.965
*
 
 Betametasone 160 (76.2) 52 (70.3) 108 (79.4) 0.137
*
 
 Dexametasone 50 (23.8) 22 (29.7) 28 (20.6) 0.175
*
 
 Full first cycle 146 (69.5) 50 (67.6) 96 (70.6) 0.650
*
 
 Full rescue cycle 8 (3.8) 2 (2.7) 6 (4.4) 0.715
∞
 
Time between the last dose of a full cycle of steroids 
and delivery (hours), median (min-max) 
 
75 (1-1148) 
 
59 (1-1148) 
 
81.5 (1-1096) 
 
0.271
¥
 
Positive group β streptococcus screening, n (%) 11 (45.8) 5 (55.6) 6 (40.0) 0.675
∞
 
Premature membrane rupture, n (%) 49 (21.1) 13 (16.0) 36 (23.8) 0.166
*
 
Peripartum antibiotics, n (%) 99 (42.3) 27 (32.5) 72 (47.7) 0.025
*
 
Placental histology, n (%)     
 Chorioamnionitis 54 (24.3) 25 (30.5) 29 (20.7) 0.101
*
 
 Funisitis 7 (3.2) 4 (4.9) 3 (2.1) 0.428
∞
 
 Vilitis 14 (6.3) 3 (3.7) 11 (7.9) 0.263
∞
 
 Vasculitis 18 (8.1) 9 (11.1) 9 (6.4) 0.220
*
 
 Hemorrhage 1 (0.5) 0 1 (0.7) 0.999
∞
 
 Ischemia 97 (43.7) 34 (41.5) 63 (45.0) 0.608
*
 
*Chi-square test, ∞Fisher’s exact test, §Independent t test, ¥Mann-Whitney U test 
** HELLP syndrome: Hemolysis, elevated liver enzymes and low platelet count Syndrome 
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Table 2 - Delivery and evolution in neonatal intensive care unit 
 Total 
(n=234) 
RDS 
(n=83) 
Without RDS 
(n=151) 
p 
Delivery, n (%)     
 Vaginal 95 (40.6) 26 (31.3) 69 (45.7) 0.032
*
 
 C-section 139 (59.4) 57 (68.7) 82 (54.3) 0.032
*
 
Apgar score, n (%)     
 1
st
 min <7 74 (31.6) 47 (56.6) 27 (17.9) <0.0001
*
 
 5
th
 min <7 22 (9.4) 17 (20.5) 5 (3.3) <0.0001
*
 
Resuscitation, n (%) 96 (41.0) 62 (74.7) 34 (22.5) <0.0001
*
 
Early nasal CPAP, n (%) 75 (32.1) 28 (33.7) 47 (31.1) 0.682
*
 
Early invasive ventilation, (%) 42 (18.1) 40 (48.8) 0 <0.0001
∞
 
Neonatal morbidities, n (%)     
 Bronchopulmonary dysplasia 15 (6.4) 15 (18.1) 0 <0.0001
∞
 
 Patent ductus arteriosus 59 (25.2) 42 (50.6) 17 (11.3) <0.0001
*
 
   Surgical treatment 6 (10.2) 6 (14.3) 0 0.002
∞
 
 Necrotizing enterocolitis (≥ grade 2A) 0 0 0 - 
 Intraventricular hemorrhage (≥ grade 3) 9 (3.9) 7 (8.5) 2 (1.3) 0.010
∞
 
 Hydrocephalus 1 (0.4) 1 (1.2) 0 0.355
∞
 
 Periventricular leukomalacia 5 (2.2) 3 (3.7) 2 (1.3) 0.346
∞
 
 Retinopathy of prematurity (≥ grade 2) 12 (5.2) 11 (13.4) 1 (0.7) <0.0001
∞
 
 Sepsis 27 (11.5) 22 (26.5) 5 (3.3) <0.0001
*
 
 Pneumonia 6 (2.6) 6 (7.2) 0 0.002
∞
 
 Pneumothorax 8 (3.4)  8 (9.6) 0 <0.0001
∞
 
 Atelectasis 7 (3.0) 7 (8.4) 0 0.001
∞
 
 Seizures 3 (1.3) 3 (3.6) 0 0.044
∞
 
 Acute renal failure 15 (6.4) 14 (16.9) 1 (0.7) <0.0001
∞
 
 Thrombocytopenia with platelet transfusion 16 (6.8) 16 (19.3) 0 <0.0001
∞
 
 Anemia with red blood cells transfusion  58 (24.8) 44 (53.0) 14 (9.3) <0.0001
*
 
 Gastroesophageal reflux 24 (10.3) 17 (20.5) 7 (4.6) <0.0001
*
 
Vasopressor support, n (%) 15 (6.4) 14 (16.9) 1 (0.7) <0.0001
∞ 
 Vasopressor support (days), median (min-max) 2 (1-25) 2.5 (1-25) 1 (1-1) 0.308
¥
 
Oxygen therapy, n (%) 82 (35.2) 64 (78.0) 18 (11.9) <0.0001
∞ 
 Oxygen therapy (days), median (min-max) 4 (1-191) 6 (1-191) 1.5 (1-6) <0.0001
¥
 
Invasive ventilation, n (%) 57 (24.4) 57 (68.7) 0 <0.0001
∞ 
 Invasive ventilation (days), median (min-max) 5 (1-88) 5 (1-88) - - 
Parenteral nutrition, n (%) 175 (76.1) 75 (93.8) 100 (66.7) <0.0001
* 
 Parenteral nutrition (days), median (min-max) 9 (1-90) 14 (1-90) 7 (1-20) <0.0001
¥
 
Surfactant, n (%) 67 (28.6) 67 (80.7) 0 <0.0001
∞ 
 Doses, median (min-max) 1 (1-5) 1 (1-5) 0 <0.0001
¥ 
First dose of surfactant (hours), median (min-max) 1 (0-24) 1 (0-24) 0 0.441
¥
 
Postnatal iv steroids, n (%)  7 (2.9) 7 (8.4) 0 0.001
∞
 
Bronchodilators, n (%) 11 (4.7) 11 (13.3) 0 <0.0001
∞
 
Inhaled steroids, n (%) 11 (4.7) 11 (13.3) 0 <0.0001
∞
 
Stay in NICU (days), median (min-max) 15 (1-191) 33 (1-191) 11 (1-61) <0.0001
¥
 
Transferred to another NICU, n (%) 59 (25.2) 10 (12.0) 49 (32.5) 0.001
*
 
 Days until transference, median (min-max) 6 (1-25) 9.5 (2-25) 5 (1-22) 0.092
¥
 
Treatment at discharge, n (%)    
 
 Bronchodilator 8 (3.4) 8 (9.6) 0 <0.0001
∞
 
 Inhaled steroids 12 (5.1) 12 (14.5) 0 <0.0001
∞
 
 Oxygen 8 (3.4) 8 (9.6) 0 <0.0001
∞
 
Deceased, n (%) 17 (7.3) 17 (20.5) 0 <0.0001
∞
 
Causes of death, n (%)     
 Intraventricular hemorrhage grade IV 6 (35.3) 6 (35.3) 0  0.647
∞
 
 Multiorgan dysfunction 6 (35.3) 6 (35.3) 0 0.647
∞
 
 Arrhythmia 1 (5.9) 1 (5.9) 0 0.941
∞
 
 Extreme prematurity 1 (5.9) 1 (5.9) 0 0.941
∞
 
 Pulmonary hypoplasia 2 (11.8) 2 (11.8) 0 0.882
∞
 
 Pulmonary hemorrhage 1 (5.9) 1 (5.9) 0  0.941
∞
 
*Chi-square test, ∞Fisher’s exact test, §Independent t test, ¥Mann-Whitney U test  
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Table 3 - Demographic and clinical characteristics according to severity of RDS 
 Mild RDS 
(n=35) 
Moderate RDS 
(n=32) 
Severe RDS 
(n=16) 
p 
Gestational age (weeks), median (min-max) 33 (27-34) 31 (24-34) 29 (23-34) 0.014
¥
 
Multiple gestation, n (%) 7 (20.0) 8 (25.0) 9 (56.2) 0.025
*
 
Prenatal Steroids, n (%) 33 (94.3) 25 (80.6) 16 (100) 0.082
∞
 
 Full first cycle 26 (78.8) 18 (72.0) 6 (37.5) 0.013
*
 
Early invasive ventilation, (%) 11 (31.4) 17 (53.1) 12 (75.0) 0.010
∞
 
Neonatal morbidities, n (%)     
 Patent ductus arteriosus with surgical treatment 3 (8.6) 0 3 (18.8) 0.044
∞
 
 Periventricular leukomalacia 0 1 (3.2) 2 (12.5) 0.043
∞
 
 Thrombocytopenia with platelet transfusion 5 (14.3) 4 (12.5) 7 (43.8) 0.035
∞
 
Vasopressor support, n (%) 1 (2.9) 7 (21.9) 6 (37.5) 0.003
∞
 
Oxygen therapy, n (%) 24 (68.6) 24 (75.0) 16 (100) 0.032
∞
 
Invasive ventilation, n (%) 18 (51.4) 25 (78.1) 14 (87.5) 0.016
¥
 
Surfactant, n (%) 22 (62.9) 29 (90.6) 16 (100) 0.001
∞ 
 Doses, median (min-max) 1 (1-2) 1 (1-5) 2 (1-4) 0.044
¥
 
*Chi-square test, ∞Fisher’s exact test, §One-Way ANOVA, ¥Kruskal-Wallis test 
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